Clinical Trial Update: A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study comparing Lilly's LY2963016 with a basal insulin after a single dose in healthy subjects; results completed and posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• LY2963016 (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2014-10-07